{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:25:17Z","timestamp":1784118317732,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China-Youth Science Fund","award":["81901713"],"award-info":[{"award-number":["81901713"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-024-01781-3","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T04:23:52Z","timestamp":1707971032000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"129","author":[{"given":"Nan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxv","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2753-6928","authenticated-orcid":false,"given":"Ketao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"5","key":"1781_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13(5):261\u2013280. https:\/\/doi.org\/10.1038\/nrgastro.2016.51","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1781_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/hbsn.2018.03.16","volume":"7","author":"EW Beal","year":"2018","unstructured":"Beal EW, Tumin D, Moris D et al (2018) Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 7(4):270\u2013276. https:\/\/doi.org\/10.21037\/hbsn.2018.03.16","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"11","key":"1781_CR3","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cncr.32803","volume":"126","author":"AA Florio","year":"2020","unstructured":"Florio AA, Ferlay J, Znaor A et al (2020) Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126(11):2666\u20132678. https:\/\/doi.org\/10.1002\/cncr.32803","journal-title":"Cancer"},{"issue":"8","key":"1781_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.6004\/jnccn.2014.0112","volume":"12","author":"AB Benson 3rd","year":"2014","unstructured":"Benson AB 3rd, D\u2019Angelica MI, Abrams TA et al (2014) Hepatobiliary cancers, version. J Natl Compr Canc Netw 12(8):1152\u20131182. https:\/\/doi.org\/10.6004\/jnccn.2014.0112","journal-title":"J Natl Compr Canc Netw"},{"key":"1781_CR5","volume-title":"Guidelines of Chinese society of clinical oncology (CSCO) biliary tract cancer","author":"Chinese Society of Clinical Oncology","year":"2022","unstructured":"Chinese Society of Clinical Oncology (2022) Guidelines of Chinese society of clinical oncology (CSCO) biliary tract cancer. People\u2019s Medical Publishing House, London"},{"issue":"14","key":"1781_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"1","key":"1781_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","volume":"6","author":"LJ Savic","year":"2017","unstructured":"Savic LJ, Chapiro J, Geschwind JH (2017) Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr 6(1):7\u201321. https:\/\/doi.org\/10.21037\/hbsn.2016.11.02","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1781_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.7150\/jca.67523","volume":"13","author":"T Sun","year":"2022","unstructured":"Sun T, Zhang W, Chen L et al (2022) A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients. J Cancer 13:1282\u20131288. https:\/\/doi.org\/10.7150\/jca.67523","journal-title":"J Cancer"},{"issue":"8","key":"1781_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s00270-022-03108-z","volume":"45","author":"D Liu","year":"2022","unstructured":"Liu D, Wang J, Ma Z et al (2022) Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety. Cardiovasc Intervent Radiol 45(8):1092\u20131101. https:\/\/doi.org\/10.1007\/s00270-022-03108-z","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1781_CR10","doi-asserted-by":"publisher","first-page":"1112500","DOI":"10.3389\/fbioe.2022.1112500","volume":"10","author":"J Wang","year":"2022","unstructured":"Wang J, Xue Y, Liu R et al (2022) DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study. Front Bioeng Biotechnol 10:1112500. https:\/\/doi.org\/10.3389\/fbioe.2022.1112500","journal-title":"Front Bioeng Biotechnol"},{"issue":"9","key":"1781_CR11","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","volume":"29","author":"RCG Martin 2nd","year":"2022","unstructured":"Martin RCG 2nd, Simo KA, Hansen P et al (2022) Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin. Ann Surg Oncol 29(9):5462\u20135473. https:\/\/doi.org\/10.1245\/s10434-022-11932-3","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1781_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72(2):288\u2013306. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.026","journal-title":"J Hepatol"},{"key":"1781_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni R (2013) New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res 19:1312\u20131314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3796","journal-title":"Clin Cancer Res"},{"key":"1781_CR14","unstructured":"US Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 26 June 2023"},{"key":"1781_CR15","unstructured":"National Health Committee of the People\u2019s Republic of China (2022) Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). https:\/\/www.hnysfww.com\/data\/article\/1642401475601352639.pdf. Accessed 1 May 2023"},{"issue":"2","key":"1781_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1055\/s-2006-941443","volume":"23","author":"JI Bilbao","year":"2006","unstructured":"Bilbao JI, Mart\u00ednez-Cuesta A, Urtasun F, Cos\u00edn O (2006) Complications of embolization. Semin Intervent Radiol 23(2):126\u2013142. https:\/\/doi.org\/10.1055\/s-2006-941443","journal-title":"Semin Intervent Radiol"},{"key":"1781_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868034","volume":"12","author":"N Wang","year":"2022","unstructured":"Wang N, Huang A, Kuang B et al (2022) Progress in radiotherapy for cholangiocarcinoma. Front Oncol 12:868034. https:\/\/doi.org\/10.3389\/fonc.2022.868034","journal-title":"Front Oncol"},{"issue":"9","key":"1781_CR18","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","volume":"29","author":"JJ Holster","year":"2022","unstructured":"Holster JJ, El Hassnaoui M, Franssen S et al (2022) Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 29(9):5528\u20135538. https:\/\/doi.org\/10.1245\/s10434-022-11439-x","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1781_CR19","first-page":"3461","volume":"11","author":"TW Mudd","year":"2021","unstructured":"Mudd TW, Guddati AK (2021) Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res 11(7):3461\u20133474","journal-title":"Am J Cancer Res"},{"issue":"4","key":"1781_CR20","first-page":"1132","volume":"11","author":"TW Mudd Jr","year":"2021","unstructured":"Mudd TW Jr, Khalid M, Guddati AK (2021) Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res 11(4):1132\u20131147","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1781_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","volume":"19","author":"RA Miksad","year":"2019","unstructured":"Miksad RA, Ogasawara S, Xia F et al (2019) Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 19(1):795. https:\/\/doi.org\/10.1186\/s12885-019-5989-2","journal-title":"BMC Cancer"},{"issue":"5","key":"1781_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G et al (2021) Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol 44(5):728\u2013738. https:\/\/doi.org\/10.1007\/s00270-021-02800-w","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"1781_CR23","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/cancers15082384","volume":"15","author":"M Owen","year":"2023","unstructured":"Owen M, Makary MS, Beal EW (2023) Locoregional Therapy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 15(8):2384. https:\/\/doi.org\/10.3390\/cancers15082384","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1781_CR24","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","volume":"20","author":"O Hyder","year":"2013","unstructured":"Hyder O, Marsh JW, Salem R et al (2013) Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 20(12):3779\u20133786. https:\/\/doi.org\/10.1245\/s10434-013-3127-y","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1781_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B et al (2020) Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6(1):51\u201359. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702","journal-title":"JAMA Oncol"},{"issue":"1","key":"1781_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/jcm9010056","volume":"9","author":"M K\u00f6hler","year":"2019","unstructured":"K\u00f6hler M, Harders F, Loh\u00f6fer F et al (2019) Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med 9(1):56. https:\/\/doi.org\/10.3390\/jcm9010056","journal-title":"J Clin Med"},{"issue":"5","key":"1781_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","volume":"41","author":"P Reimer","year":"2018","unstructured":"Reimer P, Virarkar MK, Binnenhei M et al (2018) Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-na\u00efve patients. Cardiovasc Intervent Radiol 41(5):744\u2013752. https:\/\/doi.org\/10.1007\/s00270-017-1871-2","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1781_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi C, Gramenzi A, Ascanio S et al (2016) Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer 115(3):297\u2013302. https:\/\/doi.org\/10.1038\/bjc.2016.191","journal-title":"Br J Cancer"},{"key":"1781_CR29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339\u20131343. https:\/\/doi.org\/10.1093\/annonc\/mdh351","journal-title":"Ann Oncol"},{"issue":"12","key":"1781_CR30","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30(12):1950\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdz402","journal-title":"Ann Oncol"},{"issue":"5","key":"1781_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30(5):788\u2013795. https:\/\/doi.org\/10.1093\/annonc\/mdz058","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1007\/s11547-024-01823-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000}}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01781-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:21:30Z","timestamp":1715840490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01781-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01781-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11547-024-01823-w","asserted-by":"object"}]},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Table 3 was published with errors and is now corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11547-024-01823-w","URL":"https:\/\/doi.org\/10.1007\/s11547-024-01823-w","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective cohort study was performed in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethical Review Committee of Tongji Hospital, Huazhong University of Science and Technology, and informed consent from patients to study participation was waived due to its retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}